Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

706.60INR
23 Jan 2015
Change (% chg)

Rs9.50 (+1.36%)
Prev Close
Rs697.10
Open
Rs705.00
Day's High
Rs714.65
Day's Low
Rs700.00
Volume
715,917
Avg. Vol
1,187,091
52-wk High
Rs714.65
52-wk Low
Rs305.20

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.53
Market Cap(Mil.): Rs300,773.81
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): 524.96 40.21 40.82
EPS (TTM): 1.35 -- --
ROI: -- 19.07 18.35
ROE: -- 19.85 19.25
Search Stocks

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

UPDATE 1-India's regulator clears Sun Pharma-Ranbaxy deal

(Adds details from CCI order, comments from Sun and Ranbaxy, background)

08 Dec 2014

India's antitrust regulator clears Sun Pharma-Ranbaxy deal

MUMBAI, Dec 8 - India's antitrust regulator said on Monday it has approved generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

Dec 5 - A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

05 Dec 2014

UPDATE 1-Ranbaxy says Europe bars imports from antibiotic injectables unit

* Ranbaxy says sees no significant impact on business (Recasts with statements from Ranbaxy and European regulator, adds details)

04 Dec 2014

Germany bars antibiotic drug from Ranbaxy's central India plant

MUMBAI - Indian drugmaker Ranbaxy Laboratories Ltd has been barred by from exporting the antibiotic cephalosporin to Germany from its plant in central India for not complying with standard manufacturing practices.

03 Dec 2014

Germany bars antibiotic drug from Ranbaxy's central India plant

MUMBAI, Dec 3 - Indian drugmaker Ranbaxy Laboratories Ltd has been barred by from exporting the antibiotic cephalosporin to Germany from its plant in central India for not complying with standard manufacturing practices.

03 Dec 2014

U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

Nov 20 - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

20 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks